Incannex Healthcare Inc. (IXHL)

Incannex Healthcare has moved IHL-42X into active clinical execution for obstructive sleep apnea, with DReAMzz dosing underway across 14 U.S. sites. The company also reports roughly $68.4 million in unrestricted cash, no debt, and more than A$11.2 million in non-dilutive R&D refundsreceived during 2026. Results from DReAMzz and future financing needs remain central to the investment outlook.